Jasper Therapeutics Inc
NASDAQ:JSPR
Jasper Therapeutics Inc
NASDAQ:JSPR
Price:
23.99 USD
0.5%
Updated:
May 2, 2024
Jasper Therapeutics Inc
Cash from Financing Activities
|
Jasper Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
Cash from Financing Activities
$101m
|
CAGR 3-Years
108%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Jasper Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
101m
USD
101m
USD
Based on the financial report for Dec 31, 2023, Jasper Therapeutics Inc's Cash from Financing Activities amounts to 101m USD.
What is Jasper Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
108%
108%
Over the last year, the Cash from Financing Activities growth was 168 185%. The average annual Cash from Financing Activities growth rates for Jasper Therapeutics Inc have been 108% over the past three years .
You don't have any saved screeners yet
